InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases an integration of CYTOCON DB and fIVE DB with Heta. Now Heta format is upgraded to allow direct query to databases from the QSP model code without working with database websites.
CYTOCON DB is an online database of human baseline concentrations of cytokines and cells measured in different tissues of healthy subjects and patients suffering from various pathologies. Heta format developed for QSP models encoding into Excel table was upgraded in such a way to allow results of the query to CYTOCON DB to appear in the QSP model code directly in the section describing species included in the model in form of weighted mean and weighted standard deviations for cells and cytokines concentrations. Moreover, results of the query to fIVE DB now appear in the QSP model code directly in the section describing initialization of model parameters in form of weighted mean and minimal and maximal values of model parameters (kbase, Emax/IC50, EC50/IC50, etc.) fIVE DB is an InSysBio project for in vitro experiments information collection and processing.
Such integration of CYTOCON DB and fIVE DB with Heta enables QSP modelers:
About Heta
The Heta Project is an open-source initiative dedicated to transforming the landscape of pharmacology and systems biology modeling. By developing a unified infrastructure and best practices, we empower researchers and practitioners to create dynamic quantitative models with ease and efficiency. Heta is a software tool for the development of large-scale QSP models and compilation into simulation formats.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | March 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
1.
09 Mar 2017 14:10
ISBM Enclosed Conference was held
20-22 February 2017 the 10th ISBM Enclosed Conference was held. For ten years the employees annually have been meeting together to share their scientific results and talk over future plans. ISBM did a great job in this working year.
|
10
|
11
|
12
|
|
13
|
14
|
15
1.
15 Mar 2017 11:49
Institute for Systems Biology participates in American Society for Clinical Pharmacology and Therapeutics 2017 Meeting
Institute for Systems Biology Moscow – a company, providing modeling services for innovative drug design, announced participation in ASCPT 2017 Meeting, which is held on 15-18 March in Washington, DC. ISBM will present several studies and demonstrate an updated version of platform for quantitative systems pharmacology modeling of immune response - Immune Response Template (IRT).
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
1.
28 Mar 2017 17:56
Not all therapies are effective: Institute for Systems Biology Moscow to present the results of the Alzheimer’s disease Systems Pharmacology Modeling
Moscow, Russia – March 28, 2017. On the 1st April, Tatyana Karelina, ISBM leading specialist in neurodegenerative field, will present a poster entitled "Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model" at the 13th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders to be held on March 29 - April 2, Vienna, Austria.
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
